The second day into Jose Baselga’s tenure as head of AstraZeneca Plc’s cancer research, his new boss called him in to discuss a rival company’s drug.
Under development by Daiichi Sankyo Co., it represented the latest generation of treatments the researcher had tested earlier in his career. The drug could transform the way doctors look at one of the most common forms of breast cancer, Baselga told Astra Chief Executive Officer Pascal Soriot, who was already thinking about a deal.
Jose Baselga
Source: AstraZeneca Plc
“He looked at me and said, are you sure?” Baselga said in an interview in London. “I said yes. ...